Next, we evaluated the activities of tumor growth inhibition following treatment with different ICIs, such as anti-PD-1/anti-PD-L1/anti-CTLA-4 antibodies, combined with regorafenib/cabozantinib plus chidamide-k30 regimens in CT26 tumor-bearing mice. This evidence concerns the gene CD274 and neoplasm.